Isracann Biosciences Inc.
ISCNF · OTC
8/31/2022 | 5/31/2022 | 2/28/2022 | 11/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.00 | 0.19 | -0.04 |
| FCF Yield | -2.05% | -2.21% | -3.76% | -4.86% |
| EV / EBITDA | -25.49 | -3.49 | -22.26 | -12.75 |
| Quality | ||||
| ROIC | -10.17% | -16.93% | -29.06% | -34.17% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.52 | 0.08 | 0.84 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 24.08% | 58.74% | 9.28% | -29.87% |
| Safety | ||||
| Net Debt / EBITDA | 0.65 | 0.08 | 0.51 | 0.96 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,447.81 | -2,640.45 | -3,559.21 | -2,961.68 |